CAR-T

Natural killer cells
#CAR-T #Natural killer cells #Oncology #Ovarian cancer #UCLA

Scientists develop CAR-NKT cell therapy for ovarian cancer

A new type of immunotherapy called CAR-NKT cell therapy has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.   Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced… Read More

#Cancer Research #Editor's Choice #News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Cell therapy #FDA #Galapagos #Lymphoma #Oncology

FDA RMAT designation for mantle cell lymphoma cell therapy

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).   To qualify for RMAT designation, GLPG5101 demonstrated preliminary clinical evidence suggesting it has the potential to… Read More

#News #Regulatory

CAR-T therapy for leukaemia
#CAR-T #Cell therapy #Haematology #In vivo #Lipid based nanoparticle (LNP) #NanoCell Therapeutics #Oncology

First non-viral DNA-based in vivo CAR-T generation

A new study has demonstrated the first stable, functional chimeric antigen receptor T-cells (CAR-T) cell generation in vivo using targeted lipid nanoparticles for DNA delivery.  The research evaluated NanoCell Therapeutics’ targeted lipid nanoparticle delivery system, termed NCtx, which enables the… Read More

#Cancer Research #News #Trending News

European Commission
#Autolus #CAR-T #Cell therapy #European Commission #Leukaemia #Oncology

Autolus Therapeutics’ CAR-T therapy gets EU green light

The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL).  The EC approval was based on the results of the FELIX study, an open-label, multi centre, single arm… Read More

#News #Regulatory

Cell and gene therapy
#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Manufacturing #MHRA #UK

Landmark UK legislation improves access to personalised therapies

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.  The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations… Read More

#News #Trending News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

New DDW Highlights podcast: 7 July 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In significant news this week, the FDA in the US has removed red tape that… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (30 June – 4 July) 

News round-up for 30 June – 4 July by DDW Senior Digital Content Editor Diana Turner. In significant news this week, the FDA in the US has removed red tape that limits which centres could give CAR-T therapy, in a move to improve access to the therapies. The… Read More

#News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #Haematology #Oncology

Coalition aims to double CAR-T therapy access by 2030

CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy.   By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.   As outlined in a… Read More

#News

#AbbVie #Capstan Therapeutics #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

AbbVie acquires in vivo CAR-T technology with Capstan purchase

AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs.  The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase I development for the treatment of B… Read More

#Business & Investment #News

FDA headquarters
#CAR-T #Cell therapy #FDA #Immunotherapy #Regulatory

FDA removes barriers to CAR-T access in the US

The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been removed.  The Food and Drug Administration (FDA) has determined that a REMS is no longer necessary to ensure that the benefits of these CAR T cell immunotherapies… Read More

#News #Regulatory

#Alpha-1 antitrypsin deficiency #CAR-T #Gene editing #RNA #Sickle cell disorder (SCD)

Tessera Therapeutics presents new preclinical data

Biotech Tessera Therapeutics has presented updates across its in vivo genetic medicine programmes for Alpha-1 antitrypsin deficiency (AATD), Phenylketonuria (PKU), and Sickle Cell Disease (SCD), as well as advances in in vivo T cell therapies. These data were shared across four oral presentations and three poster presentations at the American Society of Gene and… Read More

#News

CAR-T cell therapy
#CAR-T #Cell therapy #In Focus Report #Market reporting

In Focus report: Cell therapy and opportunities for new medicines

With significant investment in development and manufacturing, the cell therapy market is expected to boom in the next five years. However, despite the optimism around cell therapies, many are expensive, complicated to manufacture and come with potentially severe side effects. This report investigates how drug developers… Read More

#News

CAR-T cells attacking a cancer cell
#Cancer research #CAR-T #Cell and gene therapy #Leucid Bio #Solid tumours

First patient dosed in CAR-T therapy trial for solid tumours

Leucid Bio has dosed the first patient in the Phase I AERIAL trial evaluating the safety and clinical activity of LEU011 in patients with refractory solid tumours. Initiation of the AERIAL trial follows the successful first close of the Series A1 financing of £7.2 ($9.51) million in February 2025, co-led… Read More

#Cancer Research #News

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

#bit bio #CAR-T #CRISPR #Drug development #Drug discovery #Stem cells #Synthetic biology #Synthetic DNA

New podcast: An overview on the impact of synthetic biology

This is the latest episode of the free DDW narrated podcast, titled “An overview on the impact of synthetic biology”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Synthetic biology: Impacting drug discovery” and “Synthetic biology: Innovating in drug… Read More

#News